Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
25 Autism Trials near Maryland
Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerCM-AT for Autism
Herndon, Virginia
This trial is testing a special enzyme powder called CM-AT to help children with autism digest protein better.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:3 - 17
Key Eligibility Criteria
Disqualifiers:Seizures, Severe Trauma, Systemic Disease, Others
Must Not Be Taking:Stimulants, Non-stimulants, ADHD Meds
405 Participants Needed
Stimulant Medications for ADHD in Autism Spectrum Disorder
Charlottesville, Virginia
This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:4 - 17
Key Eligibility Criteria
Disqualifiers:Unstable Medications, Others
Must Not Be Taking:ADHD Medications
500 Participants Needed
ML-004 for Autism
Washington D.C., District of Columbia
This trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12 - 46
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
120 Participants Needed
ML-004 for Autism Spectrum Disorder
Washington D.C., District of Columbia
This trial is testing a treatment called ML-004 to see if it can help improve social communication skills in adolescents and adults with Autism Spectrum Disorder (ASD). The study will involve about 150 participants to determine its effectiveness.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 45
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
150 Participants Needed
Cariprazine for Pediatric Schizophrenia
Charlottesville, Virginia
This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Major Depressive, Schizoaffective, Intellectual Disability, Others
310 Participants Needed
Oxytocin Nasal Spray for Autism
Charlottesville, Virginia
This trial tests if giving oxytocin through a nasal spray can improve bone health in children with autism. Children with autism often have weaker bones and lower levels of oxytocin. The study aims to see if oxytocin can help make their bones stronger. Oxytocin has been investigated for its potential to treat social deficits in autism spectrum disorders, with various studies exploring its effects on social behavior and brain function.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 18
Key Eligibility Criteria
Disqualifiers:Fragile X, Tuberous Sclerosis, Others
Must Not Be Taking:Bone Medications
96 Participants Needed
Suramin for Autism
Baltimore, Maryland
Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:5 - 14
Sex:Male
Key Eligibility Criteria
Disqualifiers:Syndromic ASD, Severe Comorbidities, Organ Dysfunction, Others
Must Not Be Taking:Sulfonamides, Chlorpromazine, Anticoagulants
45 Participants Needed
CBD for Autism
Baltimore, Maryland
This trial is testing if cannabidiol (CBD) can help with anxiety, mood issues, sleep problems, and agitation in adults with autism spectrum disorder (ASD). Participants will take CBD pills for a period of time. The study aims to see if CBD is effective and safe for these psychiatric problems. Cannabidiol (CBD) has shown promise in treating psychotic symptoms and anxiety, but there is not enough high-quality evidence for its clinical use in psychiatric disorders.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Pregnancy, Others
Must Not Be Taking:Clobazam
40 Participants Needed
Transcranial Magnetic Stimulation for Autism
Newark, Delaware
There is no consensus regarding the neurological substrate underpinning ASD. The investigators describe the novel concept of "social reciprocity network" and hypothesize that aberrant connectivity/oscillatory patterns affecting this network contribute to the core deficits in ASD.
The overarching goal of this trial is to explore abnormalities involving the neuronal connectivity and oscillatory patterns within the social reciprocity network and to elucidate the role of modulating this network via rTMS in improving the above measures and social cognition in ASD. Quantitative electroencephalography (QEEG) coherence and spectral power analysis are reliable measures of neuronal connectivity and dynamics. The investigators aim to study the QEEG coherence/spectral power analysis to explore the neuronal dynamics affecting the social reciprocity network in ASD.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 18
Key Eligibility Criteria
Disqualifiers:Significant Anxiety, Seizures, Metallic Implants, Others
12 Participants Needed
Game-Based Mobile App for Autism
Newark, Delaware
The clinical study aims to develop and test a gamified mobile health app called PuzzleWalk (PW) to promote physical activity (PA) and reduce sedentary behavior (SB) in autistic adults, including those with mild intellectual disabilities (ID). The study addresses the need for tailored interventions in this population, who are at higher risk for lifestyle-related chronic health conditions due to lower PA and higher SB. The upgraded version of PuzzleWalk integrates behavior change techniques and gamification strategies, such as translating step counts into puzzle game playtime, to encourage regular PA and reduce SB. The study will evaluate the app's effectiveness on preventive health behavior changes in real-world settings. The ultimate goal is to create an effective, sustainable, and scientifically validated mobile health tool to improve the health and well-being of autistic adults.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Moderate-to-profound ID, Orthopedic Conditions
75 Participants Needed
Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:4 - 6
Key Eligibility Criteria
Disqualifiers:Non-English, Foster Care, Severe Behavior, Others
70 Participants Needed
CBT vs Mindfulness-Based Therapy for Autism
Charlottesville, Virginia
Autistic adults are at a greater risk for mental health problems compared to the general population, with 50% meeting criteria for a co-occurring psychiatric condition. Depression and anxiety are the most common of these conditions among autistic adults, contributing to long-term detrimental effects on health, day-to-day functioning, and quality of life. This study will conduct the first large-scale head-to-head comparison of the two most widely studied mental health interventions for autistic adults: cognitive-behavioral therapy (CBT) and mindfulness-based therapy (MBT). Both interventions are well-established, empirically supported treatments for depression and anxiety in the general population, and both interventions have demonstrated efficacy among autistic adults. However, their comparative effectiveness and heterogeneity of treatment effects have not been established in autistic adults. Both interventions will be delivered by telehealth.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Acute Psychosis, Intoxication, Mania, Others
300 Participants Needed
Suicide Prevention Interventions for Autism
Baltimore, Maryland
This trial is testing two methods to prevent suicide in autistic youth aged 12-24. One method involves creating a personalized safety plan, while the other adds ongoing support through periodic check-ins. The safety plan helps individuals recognize warning signs and use coping strategies, and the check-ins provide continuous support.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 99
Key Eligibility Criteria
Disqualifiers:Acute Psychosis, Intoxication, Mania, Others
1665 Participants Needed
Transcranial Direct Current Stimulation for Autism
Washington D.C., District of Columbia
This trial is testing whether brain stimulation can improve social and thinking skills in young adults with autism. The treatment involves using electrical or magnetic stimulation on specific parts of the brain. Researchers hope this will help people with autism communicate better and think more flexibly. The new method aims to enhance cognitive, motor, and social communication abilities.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 35
Key Eligibility Criteria
Disqualifiers:Neurological Condition, Brain Injury, Others
Must Not Be Taking:Psychotropic Medication
80 Participants Needed
Executive Function Group Therapy for Autism Spectrum Disorder
Washington, District of Columbia
This project explores the association between learning and cognitive flexibility by testing whether a cognitive behavioral intervention designed to improve flexibility in ASD changes learning and associated neural activation using model-based functional magnetic resonance imaging (m-fMRI). The study proposes that variability in learning mechanisms is associated with behavioral flexibility and explains differences in adaptive and treatment outcomes. The study employs a longitudinal case-controlled design in 60 14-18 year old youth with ASD at 3 time-points 8 months apart, each including m-fMRI during learning and behavioral measurement of executive and adaptive function. Aim 1 tests the hypothesis that individual variation in learning biases and their neural correlates predicts behavioral flexibility and is stable over time. Aim 2 tests plasticity of learning mechanisms induced by a cognitive-behavioral intervention for flexibility. Aim 3 tests hypothesis about intervention-induced plasticity of neural functional connectivity.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:14 - 18
Key Eligibility Criteria
Disqualifiers:Neurological Disorder, Metal Implants, Pregnancy, Others
64 Participants Needed
Social and Communication Intervention for Autism
Baltimore, Maryland
This trial tests a school program designed to help young children with autism improve their language and social skills. It focuses on preschool-aged children who need extra help in these areas. Teachers are trained to use special techniques and get feedback to improve their methods.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:3 - 6
Key Eligibility Criteria
Disqualifiers:Head Injury, Serious Physical Injury, Others
700 Participants Needed
Executive Function Treatment for Autism Spectrum Disorder
Rockville, Maryland
This trial tests a school-based program called UOT:HS for high school students with autism. The program aims to improve planning and flexibility skills through lessons and parental involvement to help students succeed after high school.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:14 - 22
Key Eligibility Criteria
Disqualifiers:Non-English Proficiency, Others
224 Participants Needed
Robot-Mediated Therapy for Autism
Baltimore, Maryland
This study is being done to examine the impact of an interactive, social robotics program in helping children with autism spectrum disorders (ASD) understand emotions and how to better recognize emotions while interacting with others. Eligible families will be randomized to either the robot intervention (n=20) or a no intervention (TAU; n=20) condition for 8-14 weeks. Assessments will occur at pre- and post-intervention as well as weekly for both conditions.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:4 - 8
Key Eligibility Criteria
Disqualifiers:IQ <70, Head Injury, Seizure, Others
40 Participants Needed
Pimavanserin for Autism Spectrum Disorder
Washington, District of Columbia
This trial is testing pimavanserin, a medication that may help reduce irritability in children and teenagers with autism. The study focuses on kids aged 5 to 17 who have this symptom. Pimavanserin works by balancing brain chemicals to help them feel calmer. The goal is to see if the medication is safe and effective over time.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:5 - 18
Key Eligibility Criteria
Disqualifiers:Not Listed
209 Participants Needed
Cognitive Behavioral Therapy for Anxiety in Autism
Baltimore, Maryland
Anxiety is very common in autistic youth. Recently, an intervention has been created by the investigators to target these symptoms in autistic youth in a community setting. The purpose of this study is to determine the feasibility of implementing this treatment in community care centers.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 17
Key Eligibility Criteria
Disqualifiers:Psychotic Disorder, Severe Suicidal Ideation, Concurrent Psychotherapy, Others
60 Participants Needed
Why Other Patients Applied
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
Telehealth Parent Coaching for Autism
Baltimore, Maryland
The primary objective of this research study is to improve outcomes involving core social-communication symptoms for young children with ASD or social communication delays by increasing access to clinically validated early behavioral intervention through a telehealth parent coaching model. The investigators will test the hypothesis that telehealth-delivered Naturalistic Developmental Behavioral Intervention parent coaching (TC) is non-inferior to in-person coaching (IPC) for the treatment of core social-communication symptoms in toddlers with either a social communication delay or ASD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 42
Key Eligibility Criteria
Disqualifiers:Non-English, Foster Care, Others
188 Participants Needed
Reinforcement Strategies for Intellectual Disabilities
Baltimore, Maryland
This study is designed to better understand how certain features of reinforcement affect learning and motivation in individuals with intellectual and developmental disabilities (IDD). Participants will take part in a series of structured teaching sessions that involve simple tasks and reward-based feedback. By changing the timing and amount of rewards, we aim to learn how these factors influence the ability to acquire and maintain new skills. This information may help improve behavioral interventions for individuals with IDD in the future. The study does not involve medications or procedures intended to change participants' health status.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 17
Key Eligibility Criteria
Disqualifiers:Severe Sensory/motor Impairments, Others
30 Participants Needed
Parent-Mediated Social Training for Developmental Delay
Baltimore, Maryland
This study is being done to examine the feasibility and impact of the Infant Achievements caregiver coaching treatment on caregiver child-engagement strategies used during play with their infant. The investigators will examine effects on infants' social and communication behavior. This randomized controlled trial will compare caregivers and infants in the Infant Achievements (IA) coaching group to caregivers and infants in the Caregiver Education (CE) no-coaching group. A total of 64 eligible participants (16 children plus their caregiver per group) will participate in the study.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:8 - 12
Key Eligibility Criteria
Disqualifiers:Head Injury, Seizure Disorder, Aggression, Others
64 Participants Needed
Functional Communication Training for Problem Behavior
Baltimore, Maryland
The goal of this study is to improve how we teach self-control and communication skills to children and adolescents with challenging behaviors. Researchers aim to find ways to make behavior-change treatments more effective and long-lasting, even when the environment or reinforcement schedules change.
The main questions this study will answer are:
Can innovative techniques help children maintain learned skills, such as asking for attention or waiting for rewards, when faced with new people, places, or situations? How do cognitive and behavioral factors, like memory, timing, and decision-making, affect the success of treatments?
Participants in this study will:
Complete assessments to identify preferred activities and understand the causes of challenging behaviors.
Learn communication skills to replace challenging behaviors, such as tantrums or crying, with more appropriate actions like asking for attention.
Participate in activities designed to understand their individual responses to different types of rewards and delays.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 17
Key Eligibility Criteria
Disqualifiers:IDD, SPB, Others
10 Participants Needed
Ruxolitinib for Alopecia Areata
Bethesda, Maryland
This trial tests if ruxolitinib, a pill that calms the immune system, can help people with APECED and severe hair loss. The medication works by blocking overactive immune signals, which may reduce body attacks and promote hair regrowth. Ruxolitinib has shown promise in treating severe alopecia areata by inducing hair regrowth in patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 75
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Heart Failure, Others
Must Be Taking:Valacyclovir
70 Participants Needed
Know someone looking for new options?
Spread the word